SCHEMBL6699861

SCHEMBL6699861

c1ccc(Oc2nc3ccccc3c3c2ncn3CCOCc2ccncc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.38
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HRH4 Q9H3N8 1/20 0.37
LMNA P02545 3/20 0.36
TLR7 Q9NYK1 2/20 0.36
HRH2 P25021 2/20 0.36
ADRA1D P25100 1/20 0.36
HTR2A P28223 1/20 0.36
ADORA2A P29274 1/20 0.36
ADRA1A P35348 1/20 0.36
NUDT1 P36639 1/20 0.36
HTR2B P41595 1/20 0.36
PDE4D Q08499 1/20 0.36
KCNH2 Q12809 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LTA4H P09960 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701754 0.94 LMNA (0.39) POLBHRH4LMNATLR7HRH2
SCHEMBL6699464 0.89 MAPT (0.40) POLBMAPTNPSR1HRH4LMNA
SCHEMBL6700922 0.86 POLB (0.39) POLBMAPTNPSR1HRH4LMNA
SCHEMBL4790554 0.85 HPGD (0.34) POLBMAPTNPSR1HRH4LMNA
SCHEMBL2059407 0.84 TLR7 (0.54) POLBLMNATLR7HRH2ADRA1D
SCHEMBL6700062 0.81 LMNA (0.38) POLBMAPTHRH4LMNATLR7
SCHEMBL6696603 0.80 L3MBTL1 (0.38) POLBMAPTLMNATLR7HRH2
SCHEMBL6702926 0.79 TLR7 (0.44) POLBMAPTHRH4LMNATLR7
SCHEMBL6695782 0.79 LMNA (0.48) POLBMAPTLMNATLR7HRH2
SCHEMBL6702016 0.77 LMNA (0.41) POLBLMNATLR7HRH2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-15 US disclosed
US-6664260-B2 Viricides; anticarcinogneic agents; induction cytokine biosynthesis 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
EP-1339715-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-03 EP disclosed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
WO-2002046193-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 POLB 3364/4885MAPT 4130/4885NPSR1 4094/4885
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 POLB 3364/4885MAPT 4130/4885NPSR1 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.